CO2024013267A2 - Profármacos de decanoato de abiraterona y uso en terapia - Google Patents

Profármacos de decanoato de abiraterona y uso en terapia

Info

Publication number
CO2024013267A2
CO2024013267A2 CONC2024/0013267A CO2024013267A CO2024013267A2 CO 2024013267 A2 CO2024013267 A2 CO 2024013267A2 CO 2024013267 A CO2024013267 A CO 2024013267A CO 2024013267 A2 CO2024013267 A2 CO 2024013267A2
Authority
CO
Colombia
Prior art keywords
abiraterone
decanoate
prodrugs
therapy
disorder
Prior art date
Application number
CONC2024/0013267A
Other languages
English (en)
Spanish (es)
Inventor
Matthew J Sharp
Jr William R Moore
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of CO2024013267A2 publication Critical patent/CO2024013267A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CONC2024/0013267A 2022-03-01 2024-09-30 Profármacos de decanoato de abiraterona y uso en terapia CO2024013267A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315240P 2022-03-01 2022-03-01
US202263425839P 2022-11-16 2022-11-16
PCT/US2023/013116 WO2023167783A1 (en) 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy

Publications (1)

Publication Number Publication Date
CO2024013267A2 true CO2024013267A2 (es) 2024-10-10

Family

ID=85724851

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0013267A CO2024013267A2 (es) 2022-03-01 2024-09-30 Profármacos de decanoato de abiraterona y uso en terapia

Country Status (12)

Country Link
US (1) US20250186463A1 (https=)
EP (1) EP4486353A1 (https=)
JP (1) JP2025508944A (https=)
KR (1) KR20240167653A (https=)
CN (1) CN119136813A (https=)
AU (1) AU2023229152A1 (https=)
CA (1) CA3243913A1 (https=)
CL (1) CL2024002613A1 (https=)
CO (1) CO2024013267A2 (https=)
IL (1) IL315174A (https=)
MX (1) MX2024010741A (https=)
WO (1) WO2023167783A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490165A (zh) * 2020-09-02 2023-07-25 普洛佩拉治疗公司 阿比特龙前药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US10792292B2 (en) * 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024533332A (ja) * 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤

Also Published As

Publication number Publication date
IL315174A (en) 2024-10-01
WO2023167783A1 (en) 2023-09-07
CL2024002613A1 (es) 2025-02-07
EP4486353A1 (en) 2025-01-08
MX2024010741A (es) 2024-09-10
AU2023229152A1 (en) 2024-09-05
JP2025508944A (ja) 2025-04-10
CN119136813A (zh) 2024-12-13
KR20240167653A (ko) 2024-11-27
US20250186463A1 (en) 2025-06-12
CA3243913A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2021010553A (es) Profarmacos de abiraterona.
DOP2022000128A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CO2024013267A2 (es) Profármacos de decanoato de abiraterona y uso en terapia
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
MX2023002478A (es) Profarmacos de abiraterona.
CL2024002903A1 (es) Conjugado de anticuerpo b7h4-farmaco y su uso
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
AR057941A1 (es) Agentes terapeuticos para el cancer de prostata
BR112021014636A2 (pt) Uso de imunoconjugados anti-ceacam5 para tratamento de câncer de pulmão
CL2019002871A1 (es) Terapia combinada para cáncer de próstata.
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
UY39368A (es) Composiciones para modular el empalme
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX2021012449A (es) Metodo para tratar tumores.
BR112022020592A2 (pt) Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
MX2022009399A (es) Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
MX2021015970A (es) Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1.
MX2020003830A (es) Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos.
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب